is tirzepatide insulin or non insulin a novel anti diabetic molecule unfold dual action | Discover Public Health Mounjaro | American Diabetes Association

Treatment Plan Return for a follow-up appointment to review results and receive your complete, customized personal treatment plan

Just 10%

is also supported by R01 HL128526, R01 HL162828 and U01 HL160226 from the NHLBI and W81XWH2210245 from the US Department of Defense

The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial 30 investigated intensive glycemic control and treatment of dyslipidemia in patients with type 2 diabetes (median baseline values for the dyslipidemia group were high-density lipoprotein cholesterol of 38 mg/dL, low-density lipoprotein cholesterol 93 mg/dL and triglycerides 162 mg/dL)

Treatment typically starts with 3 mg once daily for 30 days (an initiation dose not intended for glycaemic control), then increases to 7 mg once daily

As a once-weekly subcutaneous injectable medication typically used for the long-term management of obesity, it mimics the action of the GLP-1 hormone, which is naturally released after eating